BIORCHESTRA
Developing novel rna-based therapeutics for neuroinflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD245—368m (Dealroom.co estimates Feb 2022.)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | Seed | |
* | KRW5.0b | Late VC | |
N/A | Seed | ||
* | $45.0m | Series C | |
| Total Funding | CAD67.1m | ||